BPS offers customized services for generating BiTE® constructs and producing BiTE® antibodies, measuring the affinity for BiTE® antibody binding to antigen using interferometry (Gator™, Probe Life) or ELISA-based assay, and assessing T cell activation using reporter cell-based assays. BPS ...
doi:US20130165629 A1Yu-Shen HsuShow-Shan SheuMingi ChangMing-Chuan ChangTa-Tung YuanUSUS8961971 * Dec 19, 2012 Feb 24, 2015 Development Center For Biotechnology Bispecific T-cell activator antibody
抗体(Antibody)是一类能与抗原特异性结合的免疫球蛋白。机体的免疫系统在抗原刺激下,由B淋巴细胞分化成的浆细胞所产生的、可与相应抗原发生特异性结合。按照抗原结合特异性,可分为多克隆抗体和单克隆抗体。这…
Bispecific antibody technical note discusses important elements of bispecific antibodies and describes GenScript capability in bispecific antibody production.
Despite recent advances in frontline therapy for diffuse large B-cell lymphoma (DLBCL), at least a third of those diagnosed still will require second or further lines for relapsed or refractory (rel/ref) disease. A small minority of these can be cured wi
CEA/CD3-bispecific T cell-engaging (BiTE) antibody-mediated T lymphocyte cytotoxicity maximized by inhibition of both PD1 and PD-L1. Cancer Immunol Immunother 2015; 64:677-88; PMID:25742933; http://dx.doi.org/10.1007/s00262-015-1671-y...
CD3 bispecific antibody (CD3 bsAb) therapy is clinically approved for refractory hematological malignancies, but responses in solid tumors have been limited so far. One of the main hurdles in solid tumors is the lack of sufficient T-cell infiltrate. Here, we show that pre-treatment vaccination, ...
CAMBRIDGE, Mass.,ROTTERDAM, Netherlands, and SUZHOU,China,Aug. 21, 2020/PRNewswire/ -- Harbour BioMed (HBM), a global, clinical-stage, innovative biopharmaceutical company, presented its newly discovered Bispecific Antibody - BCMA x CD3 (HBM7020) at the Cell engager Summit. HBM7020 was develop...
A bi-specific antibody that binds both T cells and a tumor-specific intracellular antigen shows therapeutic promise in mouse models of cancer. Intracellular tumor antigens presented on the cell surface in the context of human leukocyte antigen (HLA) mole
Anti-hCD19-CD3 is a bispecific antibody that recognizes two human cell markers: hCD19, which is expressed on the surface of (malignant) B cells, and hCD3 which is part of the T cell receptor. This antibody features blinatumomab’s single-chain variable fragments (scFv) joined by a glycin...